An observational study in Endometriosis, sponsored by University Hospital, Lille. Not yet recruiting at 1 site in France. Open to female participants aged 18 Years to 43 Years. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by University Hospital, Lille · Observational
This non-interventional study aims to assess the impact of an endometriosis diagnosis obtained through a salivary test (Ziwig Endotest®) on pain-related cognitions, quality of life, mood, and treatment adherence, comparingthese outcomes with those of individuals who underwent the same salivary test but received a negative result and were therefore not diagnosed with endometriosis.
Participation in this study will contribute to advancing research in the field of endometriosis diagnosis and multidisciplinary management by expanding current knowledge of diagnostic protocols and their impact on pain, quality of life, treatment adherence, and potential psychiatric comorbidities. The investigators hope to enhance understanding of endometriosis and pelvic pain symptomatology in order to develop new therapeutic strategies, including psychological interventions or integrated psychological care, that better address the needs and specific characteristics of patients whether or not they receive a diagnosis of endometriosis.
929 studies on the registry are indexed under Endometriosis; 267 are open to participants now.
This study's planned enrollment of 50 is below the median of 122 across 356 observational studies indexed under Endometriosis.
Browse Endometriosis studies →University Hospital, Lille is the lead sponsor of 631 studies on the registry; 142 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients referred for suspected endometriosis, with negative imaging findings and for whom an endotest has been indicated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Changes in pain catastrophizing 1 month after being informed of the results of the saliva test among patients diagnosed with endometriosis and among patients not diagnosed with endometriosis.
Change in the Pain Catastrophizing Scale score between baseline and 1 month after the announcement of the salivary test results. Use : Questionnaire Pain Catastrophizing scale-13 items divided into three dimensions: "rumination," "magnification," and "helplessness"-scored on a scale of 0 to 4-maximum total score of 52 points.
Time frame: 1 month + 3 weeks
Changes 1 month after the consultation during which the results of the salivary test for pain catastrophizing were announced, based on the diagnosis of endometriosis.
Change from baseline to 1 month after the announcement of the salivary test results in the Pain Catastrophizing Scale score. Use : Questionnaire Pain Catastrophizing scale-13 items divided into three dimensions: "rumination," "magnification," and "helplessness"-scored on a scale of 0 to 4-maximum total score of 52 points.
Time frame: 6 months + 3 weeks
Changes at 1 month and 6 months after the consultation during which the saliva test results were announced, based on whether endometriosis was diagnosed: • Quality of life • Anxiety and depressive symptoms • Treatment adherence
Change from baseline to 1 month after the results were announced, and from baseline to 6 months after the results were announced. Use: * Endometriosis Health Profile-30 questionnaire (Quality-of-life score specific to women with endometriosis) - divided into several themes: general (focusing particularly on pain and psychological impacts), work, children, sexual relations, healthcare providers, treatment, and difficulties conceiving - 53 items rated on a scale of 1 to 5, * World Health Organization Quality of Life (Quality of life score in the domains of "physical health," "psychological well-being," "social relationships," and "environment") - 26 items rated on a 5-point scale with a maximum total score of 130, * Hospital Anxiety and Depression Scale questionnaire (Anxiety and depression score) - a two-part score consisting of 7 items each, rated on a 21-point scale, * Medication Adherence Report Scale (Therapeutic compliance) - 10 items - score out of 10.
Time frame: 6 months + 3 weeks
Changes at 6 months following the consultation during which the results of the salivary test for pain catastrophizing were reported, based on the diagnosis of endometriosis.
To compare the change in pain catastrophizing at 6 months following the consultation disclosing the salivary test results, between patients diagnosed with endometriosis and those not diagnosed with endometriosis. Use : Questionnaire Pain Catastrophizing scale-13 items divided into three dimensions: "rumination," "magnification," and "helplessness"-scored on a scale of 0 to 4-maximum total score of 52 points.
Time frame: 6 months + 3 weeks
Other open studies at CHU de Lille, Lille
Open a list, then choose Watch this search to get new studies there in a weekly email.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Jun 2028, 19 months later.
Of 153 non-industry observational studies under Endometriosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 19 months is below that.
Counting every sponsor, half of 182 studies reached it within 30 months; a quarter within 14 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.